Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROGRESS: Lopinavir/Ritonavir + Raltegravir vs Standard of Care in HIV
NCT00711009Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Jul 2008
- Primary completion
- Nov 2009
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of raltegravir in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Abbott Laboratories. Primary endpoints: Percentage of Participants Responding (Plasma HIV-1 RNA < 40 copies/mL) Based on FDA TLOVR Algorithm at 48 weeks, Percentage of Participants With Moderate or Severe Treatment-emergent, Drug-related Adverse Events at 96 weeks and 1 more. Started Jul 2008; status: completed.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00711009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00711009.